Wall Street analysts expect Vital Therapies Inc (NASDAQ:VTL) to post ($0.30) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Vital Therapies’ earnings. Vital Therapies reported earnings per share of ($0.37) during the same quarter last year, which suggests a positive year over year growth rate of 18.9%. The firm is scheduled to report its next earnings report on Tuesday, March 6th.

According to Zacks, analysts expect that Vital Therapies will report full-year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.27) to ($1.26). For the next financial year, analysts anticipate that the business will post earnings of ($1.27) per share, with EPS estimates ranging from ($1.33) to ($1.21). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Vital Therapies.

Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings data on Wednesday, October 25th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. During the same quarter in the prior year, the firm earned ($0.32) EPS.

VTL has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Vital Therapies from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. BidaskClub upgraded shares of Vital Therapies from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th. ValuEngine upgraded shares of Vital Therapies from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 21st. Finally, Raymond James Financial reiterated a “buy” rating on shares of Vital Therapies in a research report on Tuesday, December 5th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $6.00.

Shares of Vital Therapies (VTL) traded down $0.15 during midday trading on Monday, hitting $6.00. 149,200 shares of the company were exchanged, compared to its average volume of 141,844. Vital Therapies has a fifty-two week low of $2.25 and a fifty-two week high of $6.70. The company has a market capitalization of $253.24, a PE ratio of -4.44 and a beta of 5.12.

In other Vital Therapies news, Director Muneer A. Satter purchased 50,000 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were purchased at an average cost of $4.77 per share, for a total transaction of $238,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Muneer A. Satter purchased 150,000 shares of the company’s stock in a transaction on Monday, December 11th. The stock was acquired at an average price of $4.89 per share, for a total transaction of $733,500.00. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 300,000 shares of company stock worth $1,520,000. 32.60% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. raised its position in Vital Therapies by 0.9% in the third quarter. Victory Capital Management Inc. now owns 2,603,089 shares of the company’s stock worth $13,145,000 after acquiring an additional 23,810 shares in the last quarter. Granahan Investment Management Inc. MA raised its position in Vital Therapies by 51.4% in the third quarter. Granahan Investment Management Inc. MA now owns 388,282 shares of the company’s stock worth $1,961,000 after acquiring an additional 131,828 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Vital Therapies by 261.4% in the second quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock worth $676,000 after acquiring an additional 168,705 shares in the last quarter. Susquehanna International Group LLP bought a new stake in Vital Therapies in the second quarter worth about $268,000. Finally, Dowling & Yahnke LLC bought a new stake in Vital Therapies in the third quarter worth about $252,000. Hedge funds and other institutional investors own 24.28% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/15/vital-therapies-inc-vtl-expected-to-post-earnings-of-0-30-per-share.html.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Get a free copy of the Zacks research report on Vital Therapies (VTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.